In Youth With ADHD, New-Onset Psychosis Up With Amphetamines
THURSDAY, March 21, 2019 -- For adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD), new-onset psychosis occurs more often with amphetamine use versus methylphenidate use, according to a study published in the March 21... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2019 Category: Pharmaceuticals Source Type: news

Some ADHD Meds Tied to a Higher Psychosis Risk Than Others Some ADHD Meds Tied to a Higher Psychosis Risk Than Others
Amphetamines are associated with a higher psychosis risk than methylphenidate in young patients who take these agents to treat attention deficit hyperactivity disorder.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 20, 2019 Category: Primary Care Tags: Psychiatry News Source Type: news

With ADHD, amphetamine has double the psychosis risk of methylphenidate
(Reuters Health) - Children and young adults with attention deficit-hyperactivity disorder (ADHD) who are treated with the stimulants amphetamine or methylphenidate face a small but significant risk of developing psychosis, with amphetamine products twice as likely to spark at problem, researchers say. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Popular Spice Rivals Stimulant for ADHD Popular Spice Rivals Stimulant for ADHD
The popular and expensive spice saffron appears to be as effective as the stimulant methylphenidate in treating symptoms in youngsters with ADHD, new research suggests.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Adhansia XR (Methylphenidate Hydrochloride Extended-release Capsules) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2019 Category: Drugs & Pharmacology Source Type: news

Ritalin drives greater connection between brain areas key to memory, attention
(University of Wisconsin-Madison) Louis Populin and collaborators at the University of Wisconsin-Madison collaborators published a study this week in the Journal of Neuroscience describing increased connections between key parts of the brains of monkeys who have taken methylphenidate (Ritalin). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2018 Category: International Medicine & Public Health Source Type: news

Possible Tie to First-Line ADHD Drug and Psychotic Symptoms Possible Tie to First-Line ADHD Drug and Psychotic Symptoms
Noting the quality of the data may be questionable, researchers are warning clinicians about the possibility that methylphenidate may carry a risk for hallucinations and other psychotic symptoms in kids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms
(Exeley Inc.) One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms. Research published in the SJCAPP says that possible adverse symptoms may affect 1.1 percent -- 2.5 percent of ADHD patients treated with methylphenidate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 22, 2018 Category: International Medicine & Public Health Source Type: news

Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 17, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Good First - Choice Pediatric ADHD Drug
For adults, amphetamines are reasonable first choice to treat attention - deficit hyperactivity disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 17, 2018 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Neurology, Nursing, Pediatrics, Pharmacy, Psychiatry, Journal, Source Type: news

Methylphenidate Good First-Choice Pediatric ADHD Drug
THURSDAY, Aug. 16, 2018 -- Methylphenidate should be considered as a first choice for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents, while amphetamines should be considered as a first choice in adults,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears First ADHD Bedtime Medication FDA Clears First ADHD Bedtime Medication
Jornay PM is a novel formulation of methylphenidate taken in the evening instead of first thing in the morning to provide early-morning control of attention-deficit/hyperactivity disorder (ADHD) symptoms.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Methylphenidate Best First-Line Drug Choice for ADHD in Kids Methylphenidate Best First-Line Drug Choice for ADHD in Kids
Methylphenidate appears to be the best first-line drug choice for attention- deficit/hyperactivity disorder (ADHD) in children and adolescents, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)August 09, 2018 --Ironshore Pharmaceuticals& Development, Inc. ( “Ironshore”) a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 10, 2018 Category: Drugs & Pharmacology Source Type: news

Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
The researchers compared seven ADHD drugs -- amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil -- and a placebo over 12 weeks of treatment. (Source: WebMD Health)
Source: WebMD Health - August 8, 2018 Category: Consumer Health News Source Type: news

Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
WEDNESDAY, Aug. 8, 2018 -- Researchers have identified what they describe as the safest, most effective short-term drug treatments for attention deficit/hyperactivity disorder (ADHD). It's methylphenidate for kids and amphetamines for adults,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2018 Category: General Medicine Source Type: news

Ritalin-type drugs best to treat ADHD in children, shows study
Methylphenidate drugs safest and most effective while adults do better on amphetaminesRitalin and other drugs of the same class are the most effective and safest medications to prescribe for children with attention deficit hyperactivity disorder (ADHD), according to a major scientific review.The review of ADHD drugs shows that they work, and work well, in spite of concerns among the public and some doctors that children in the UK are being overmedicated. Ofsted ’s chief inspector, Amanda Spielman, has likened the drugs to a “chemical cosh” and claimed they were being overprescribed, disguising bad behavio...
Source: Guardian Unlimited Science - August 8, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Attention deficit hyperactivity disorder Mental health UK news Source Type: news

Methylphenidate best drug for hyperactive kids in short-term
But consider non-drug options first, concludes pooled analysis of data from 133 trials Related items fromOnMedica Monthly testing with isotretinoin might be unnecessary CBT helps children to kick obsessions Lorazepam no better than diazepam for child seizures Broader definition of ADHD raises risk of needless treatment One in 10 children in phase I cancer trials respond to drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 8, 2018 Category: UK Health Source Type: news

Meds not the only answer for ADHD | Letters
There need to be national multi-agency collaborative pathways for the holistic assessment of children with attention difficultiesWe, as chartered psychologists (BPS), are delighted that the inadequate provision for children with mental health difficulties in the UK was highlighted (Shocking failures on children with ADHD, 4 August). We agree with the findings that there are considerable local differences in practice in this field. We note with concern the reported rise in prescriptions for stimulant drugs such as Ritalin (methylphenidate) between 2010 and 2015. We should not fall into the trap of believing that diagnosis a...
Source: Guardian Unlimited Science - August 6, 2018 Category: Science Authors: Letters Tags: Attention deficit hyperactivity disorder Society Health Mental health NHS Conservatives Politics Psychology Science Source Type: news

UB research suggests how stimulant treatments for ADHD work
(University at Buffalo) Stimulant medications are an effective treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). In the classroom, parents and teachers say that medications like methylphenidate (MPH) can reduce symptoms and improve behavior.Although stimulants have been in use for decades to treat ADHD in school-aged children, just how they work hasn't been clear. But the results of a new study in The Journal of Child Psychology and Psychiatry is filling in critical gaps about the role of improved cognitive functions. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 27, 2018 Category: International Medicine & Public Health Source Type: news

Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

Huge surge in kids poisoned by ADHD pills since 2000
Between 2000 and 2014, around 10,000 American children under 19 were hospitalized, and three died after taking methylphenidate or amphetamine, a new study reveals. (Source: the Mail online | Health)
Source: the Mail online | Health - May 21, 2018 Category: Consumer Health News Source Type: news

Unnecessary And Accidental Use Of ADHD Drugs Increases Over 60%, Study Suggests
(CNN) — Exposure to common medications used to treat attention deficit hyperactivity disorder has increased by more than 60% in US children and adolescents, according to a new study. The study, published Monday in the journal Pediatrics, looked at all calls to US poison control centers for unintentional or intentional exposure to ADHD medications between 2000 and 2014 among children and adolescents. The researchers found that the number of calls increased from 7,018 in 2000 to 11,486 in 2014 — a 64% increase. According to the study’s authors, “exposure” refers to the unnecessary ingestion, inh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 21, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health ADHD Local TV Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

April 2018 RxNorm Release Available for Download
The RxNorm April 2018 Release is now available for download. A new Qualitative Distinction (QD) modifier “BX Rating” is included to distinguish generic methylphenidate products not therapeutically equivalent to the brand-name drug Concerta. (Source: UMLS News)
Source: UMLS News - April 13, 2018 Category: Databases & Libraries Source Type: news

Study points to potential misuse/abuse of ADHD drugs
(Wiley) A new British Journal of Clinical Pharmacology study indicates that methylphenidate, a central nervous system stimulant approved to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, may be subject to misuse and/or abuse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 7, 2018 Category: International Medicine & Public Health Source Type: news

Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta(R)
BRIDGEWATER, N.J., Feb. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate is an AB-rat... Biopharmaceuticals, Generics, Product Launch Amneal Pharmaceuticals, methylphenidate, Concerta (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2018 Category: Pharmaceuticals Source Type: news

Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Hydrochloride (QUILLICHEW ER) Extended-Release Chewable Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 22, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension (New - Currently in Shortage
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 22, 2018 Category: Drugs & Pharmacology Source Type: news

Ritalin During Pregnancy May Raise Risk of Heart Defect in Baby
A new study found a small increased risk of having a baby with a heart defect if Ritalin/Concerta  (methylphenidate) was taken by the mother-to-be. (Source: WebMD Health)
Source: WebMD Health - December 13, 2017 Category: Consumer Health News Source Type: news

ADHD drug use in pregnancy increases risk of heart defects, study finds
The attention-deficit hyperactivity disorder drug methylphenidate is associated with an increased risk of heart defects in infants whose mothers take the medication during pregnancy, according to a study published Wednesday in the journal JAMA Psychiatry. (Source: CNN.com - Health)
Source: CNN.com - Health - December 13, 2017 Category: Consumer Health News Source Type: news

ADHD Meds During Pregnancy Appear To Have Low Risk Of Birth Defects
Most ADHD medications appear to have no increased risk for birth defects except a very small increased risk for heart defects with methylphenidate use in the first trimester. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2017 Category: Pharmaceuticals Authors: Tara Haelle, Contributor Source Type: news

Extended-Release Methylphenidate Oral Tablets Extended-Release Methylphenidate Oral Tablets
A newly approved extended-release formulation of methylphenidate may be another option for the management of ADHD in children.Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 5, 2017 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: a Taiwan nationwide population-based cohort study - Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, McIntyre RS, Kelsen BA, Wang TN, Chen VC.
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) youths have increased suicide risk. Nevertheless, the beneficial effects of methylphenidate (MPH) on suicide attempt have received relatively little attention. AIMS: To investigate the MPH usage a... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Stimulant Cuts Apathy, Improves Cognition in Mild Alzheimer's Stimulant Cuts Apathy, Improves Cognition in Mild Alzheimer's
Improved cognition among older veterans with mild Alzheimer's disease taking methylphenidate was somewhat unexpected.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 3, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

New delayed-release stimulant improves morning ADHD symptoms and all-day functioning
(Mary Ann Liebert, Inc./Genetic Engineering News) A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2017 Category: International Medicine & Public Health Source Type: news

A naturalistic comparison of methylphenidate and risperidone monotherapy in drug-naive youth with attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder and aggression - Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
BACKGROUND/PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) are frequently co-occurring in youth, but data about the pharmacological management of this comorbidity are scarce, especially when impulsive aggres... (Source: SafetyLit)
Source: SafetyLit - August 25, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

methylphenidate hydrochloride (Quillivant XR)
Title: methylphenidate hydrochloride (Quillivant XR)Category: MedicationsCreated: 7/24/2014 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - August 8, 2017 Category: Pediatrics Source Type: news

Association of risk of suicide attempts with methylphenidate treatment - Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, H äge A, Rosenthal E, Wong ICK.
IMPORTANCE: Patients with attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of attempting suicide. Stimulants, such as methylphenidate hydrochloride, are the most common treatment for ADHD, but the association between their therapeut... (Source: SafetyLit)
Source: SafetyLit - July 29, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Methylphenidate-Suicide Link Doesn't Appear Causal (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD Any link between the ADHD drug methylphenidate and suicide attempts does not appear to be causal, according to an observational study in JAMA Psychiatry.Using a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 27, 2017 Category: Primary Care Source Type: news

Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users - Bjarnadottir GD, Johannsson M, Magnusson A, Rafnar BO, Sigurdsson E, Steingrimsson S, Asgrimsson V, Snorradottir I, Bragadottir H, Haraldsson HM.
BACKGROUND AND AIMS: Methylphenidate (MPH) is a prescription stimulant used to treat attention-deficit hyperactivity disorder. MPH is currently the preferred substance among most intravenous (i.v.) substance users in Iceland. Four types of MPH preparations... (Source: SafetyLit)
Source: SafetyLit - June 28, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Another extended-release ADHD drug wins FDA nod
Days after Neos Therapeutics (NSDQ:NEOS) nabbed U.S. regulatory approval for its controlled-release formulation of methylphenidate, Shire (NSDQ:SHPG) said it won a nod from the FDA for its long-acting ADHD drug. The drug, Mydayis, is made up of the same active ingredient in Shire’s ADHD treatment Adderall XR – amphetamine – but it is designed to last up to 16 hours. Adderall XR is formulated to control symptoms in patients for up to 12 hours. Get the full story at our sister site, Drug Delivery Business News. The post Another extended-release ADHD drug wins FDA nod appeared first on MassDev...
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Shire Plc. Source Type: news

Controlled-release ADHD drug wins FDA approval
Neos Therapeutics (NSDQ:NEOS) won FDA approval yesterday for its controlled-release formulation of an old ADHD drug, methylphenidate. The company touts its product, Cotempla XR-ODT, as the 1st methylphenidate tablet designed to release medication over time instead of all at once. Get the full story at our sister site, Drug Delivery Business News. The post Controlled-release ADHD drug wins FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat neostherapeutics Source Type: news

FDA Clears New Methylphenidate Formulation for ADHD FDA Clears New Methylphenidate Formulation for ADHD
Cotempla XR-ODT is a once-daily extended-release orally disintegrating tablet formulation of methylphenidate for patients aged 6 to 17 years with ADHD.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 19, 2017 Category: Drugs & Pharmacology Source Type: news

The effects of methylphenidate on the neural signatures of sustained attention - Dockree PM, Barnes JJ, Matthews N, Dean AJ, Abe R, Nandam LS, Kelly SP, Bellgrove MA, O'Connell RG.
We examined how MPH influenced known electrophysiological precursors of lapsing attenti... (Source: SafetyLit)
Source: SafetyLit - June 14, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news